# US 10,245,325 B2 · Methods and compositions for the sustained release of chromium > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 10,245,325 B2 - Document ID: US10245325B2 - Status: Granted - Kind: B2 - Application number: 15/620,542 - Filed: 2017-06-12 - Published: 2017-10-26 - Granted: 2019-04-02 - Earliest claimed: 2007-03-13 - Assignees: JDS Therapeutics, LLC - Applicants: JDS Therapeutics, LLC - Inventors: James R. Komorowski - Web page: https://patentgrep.com/patent/US10245325B2 ## CPC - A61K 47/547: {Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent} - A23L 33/165: Complexes or chelates - A61K 31/00: Medicinal preparations containing organic active ingredients - A61K 31/28: Compounds containing heavy metals - A61K 31/4172: Imidazole-alkanecarboxylic acids, e.g. histidine - A61K 31/4402: only substituted in position 2, e.g. pheniramine, bisacodyl - A61K 31/445: Non condensed piperidines, e.g. piperocaine - A61K 33/24: Heavy metals; Compounds thereof - A61K 47/545: {Heterocyclic compounds (A61K47/558 takes precedence)} - A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00) - A61P 3/06: Antihyperlipidemics - A61P 3/08: for glucose homeostasis (pancreatic hormones A61P5/48) - A61P 3/10: for hyperglycaemia, e.g. antidiabetics - A61P 5/50: for increasing or potentiating the activity of insulin - A61P 9/00: Drugs for disorders of the cardiovascular system - A23V 2002/00: Food compositions, function of food ingredients or processes for food or foodstuffs - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - A23V: INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION ## Abstract Provided herein are compositions for the administration of chromium that include at least two components: a hydrophilic chromium complex and a lipophilic chromium complex, and methods of using the same. Also provided are compositions for the administration of chromium that include a first “fast-acting” chromium complex and a second “slow-acting” chromium complex, wherein the first chromium complex is absorbed more quickly than the slow-acting chromium complex, and methods of using the same. Also provided herein are methods for treating, preventing, and improving conditions associated with cardiometabolic syndrome, by identifying a subject in need of treatment, prevention, or improvement of a condition associated with cardiometabolic syndrome, and providing a therapeutically effective amount of a composition comprising a fast-acting chromium complex and a slow-acting chromium complex, to the individual. ## Claims ### Claim 1 A composition comprising: a chromium complex comprising: an amount of a fast-acting chromium complex; and an amount of a slow-acting chromium complex; wherein the fast-acting chromium complex is absorbed more quickly by an individual to whom it is administered than the slow-acting chromium complex; wherein the amount of a fast acting chromium complex and the amount of the slow-reacting chromium complex are formulated to have a molar ratio of chromium between 1:10 and 10:1. ### Claim 2 (depends on 1) The composition of claim 1, wherein the chromium complex is a hydrophobic chromium complex. ### Claim 3 (depends on 1) The composition of claim 1, wherein the fast-acting chromium complex is hydrophilic and the slow-acting chromium complex is lipophilic. ### Claim 4 (depends on 1) The composition of claim 1, wherein the slow-acting chromium complex is lipophilic. ### Claim 5 (depends on 1) The composition of claim 1, wherein the fast-acting chromium complex is hydrophilic. ### Claim 6 (depends on 1) The composition of claim 1, wherein the amount of the fast-acting chromium complex and the amount of the slow-acting chromium complex are formulated to have a molar ratio of chromium between 1:8 and 8:1. ### Claim 7 (depends on 1) The composition of claim 1, wherein the amount of the fast-acting chromium complex and the amount of the slow-acting chromium complex are formulated to have a molar ratio of chromium between 1:4 and 4:1. ### Claim 8 (depends on 1) The composition of claim 1, wherein the amount of the fast-acting chromium complex and the amount of the slow-acting chromium complex are formulated to have a molar ratio of chromium between 1:2 and 2:1. ### Claim 9 (depends on 1) The composition of claim 1, wherein the amount of the fast-acting chromium complex and the amount of the slow-acting chromium complex are formulated to have a molar ratio of chromium of about 1:1. ### Claim 10 (depends on 1) The composition of claim 1, wherein the fast-acting chromium complex is a chromium histidinate complex. ### Claim 11 (depends on 1) The composition of claim 1, wherein the fast-acting chromium complex is a chromium nicotinate complex. ### Claim 12 (depends on 1) The composition of claim 1, wherein the fast-acting chromium complex is selected from the group consisting of chromium acetate, chromium chloride, chromium histidinate, and chromium nicotinate, or any combination thereof. ### Claim 13 (depends on 1) The composition of claim 1, wherein the fast-acting chromium complex is selected from the group consisting of chromium histidinate, chromium trihistidinate, chromium polyhistidinate, or any combination thereof. ### Claim 14 (depends on 1) The composition of claim 1, further comprising metformin. ### Claim 15 (depends on 1) The composition of claim 1, further comprising a pharmaceutically acceptable vehicle. ### Claim 16 (depends on 1) The composition of claim 1, wherein the slow-acting chromium complex is selected from the group consisting of chromium picolinate, chromium tripicolinate, or a combination thereof. ### Claim 17 (depends on 1) The composition of claim 1, wherein the slow-acting chromium complex is chromium picolinate. ### Claim 18 (depends on 1) The composition of claim 1, wherein the slow-acting chromium complex is chromium tripicolinate. ### Claim 19 (depends on 1) The composition of claim 1, wherein the slow-acting chromium complex provides a glucose lowering effect. ### Claim 20 (depends on 1) The composition of claim 1, wherein the slow-acting chromium complex provides a glucose stabilization effect for at least 10 hours.